Company profilePharmaceutical#669 of 1,318 in Pakistan✓ No DRAP alerts

LEO/ZAMZAM

Pharmaceutical company · 15 brands · 17 molecules

Ranked #2 of 19 companies in Gonadotropins And Other Ovulation Stimulants

15 registered products 16 pharmaceutical brands 17 distinct molecules 0 DRAP alerts

Company overview

15
registered products
16
pharmaceutical brands
17
distinct molecules
12
therapeutic classes
0
DRAP alerts

LEO/ZAMZAM is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 15 product registrations across 17 distinct molecules. Its portfolio is concentrated in Gonadotropins And Other Ovulation Stimulants and Skin Conditions. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by LEO/ZAMZAM

10 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Other Anti-Baterials 1

Top molecules by brand count

Fusidic Acid3 brands
Calcipotriol2 brands
Menotropin1 brand
Chorionic Gonadotrophin (Human Chorionic Gonadotrophin1 brand
Hcg)1 brand
Fusidic Acid Inj1 brand
Eperisone1 brand
Mometasone1 brand

Therapeutic classes

Gonadotropins And Other Ovulation Stimulants · 3Skin Conditions · 3Corticosteroid Combinations, Topical · 2Antipsoriatics · 2Other Anti-Baterials · 1Antispasmodic & Anticholinergic · 1Corticosteroid, Plain · 1Antihistamines For Systemic Use · 1Vitamin A, D & Combinations · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Anti-Acne Preparations · 1Muscle Relaxant · 1

Conditions treated

Infection/Allergy · 3

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO7 products · Rs 443.5 – Rs 3,166.2
Servaid3 products · Rs 431.15 – Rs 3,060.6
Median across source: Rs 666.7

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.8 shared molecules
CRYSTOLITE PHARMACEUTICALS6 shared molecules
ALZA Pharma6 shared molecules
AMBROSIA PHARMACEUTICALS6 shared molecules
LINEAR PHARMA6 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BIO LABS (PVT) LTD. holds 136 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
MEDERA PHARMACEUTICALS (PVT) LTD. holds 54 molecules not in this portfolio
AcyclovirAmiodaroneAmlodipineArtemetherAzithromycinBenzoyl Peroxide
Martin Dow Pharmaceuticals (Pvt) Ltd. holds 142 molecules not in this portfolio
AmlodipineApixabanArtemetherAspirinAzithromycinBetamethasone , Topical

Get the full profile for LEO/ZAMZAM

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.